Saying you will be running clinical trials is one of those things you put in a paper to make it sound more exciting and have it published in high impact journal. Not so much a lie, but an aspiration.
I can say for certain that the reason that COH hasn’t asked for GMP Bisantrene has nothing to do with the IP licensing agreement.
I can also tell you from bitter experience that citations have little impact on grant funding. I am not alone in this and many, many fantastic discoveries never make it into the clinic that should.
- Forums
- ASX - By Stock
- RAC
- Ann: Zantrene AML trial in Israel advances to Phase 2
Ann: Zantrene AML trial in Israel advances to Phase 2, page-153
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M |
Open | High | Low | Value | Volume |
$1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3105 | $1.94 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.95 | 7574 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3105 | 1.940 |
2 | 30000 | 1.900 |
1 | 4861 | 1.880 |
1 | 3000 | 1.850 |
1 | 30000 | 1.840 |
Price($) | Vol. | No. |
---|---|---|
1.950 | 7574 | 1 |
1.995 | 10037 | 1 |
2.000 | 8000 | 3 |
2.020 | 4000 | 1 |
2.040 | 2000 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |